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ABSTRACT 
INTRODUCTION: One-third of Medicare beneficiaries are enrolled in Medicare Advantage (MA). Yet, 
little is known about MA beneficiaries diagnosed with Alzheimer’s disease (AD) and AD-related 
dementias (AD/ADRD).   
METHODS: We calculated the prevalence of AD/ADRD diagnoses in 2014 and 2016 in three MA 
plans. We determined the demographic characteristics of beneficiaries diagnosed with AD/ADRD, 
and whether they disenrolled from the MA plan for any reason within 364 days from the index date.  
RESULTS: In 2014 and 2016 the overall prevalence of AD/ADRD diagnoses was 5.7% and 6.5%, 
respectively. In 2016, AD/ADRD beneficiaries were on average 82.4 (SD=7.3) years of age, 61.8% 
female, and had multiple comorbidity.  By 364 days post-index date, 32% of beneficiaries with 
AD/ADRD had disenrolled from their plan. The demographic characteristics of 2014 beneficiaries 
with diagnosed AD/ADRD were similar to their 2016 counterparts.   




Over five million Americans currently live with Alzheimer’s disease (AD) and AD-related 
dementias (AD/ADRD) and this number is expected to increase substantially in the coming decades.1 
These high-need, high-cost patients are vulnerable to receiving low quality, poorly coordinated care 
that leads to adverse health outcomes, poor quality of life, and misuse of resources.2-4 Maximizing 
the value of care provided to this growing population is a critical health policy challenge.5  
Much of our understanding about the characteristics of people with AD/ADRD diagnoses 
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representative surveys. These studies estimate the prevalence of diagnosed AD/ADRD in the United 
States to be 7%-14%.6-11 Yet, one-third of Medicare beneficiaries are enrolled in Medicare Advantage 
(MA) plans.12 Little is known about AD/ADRD for the population enrolled in MA.  
As MA grows in popularity, it is vital to understand the characteristics of plans’ most 
vulnerable beneficiaries including people living with AD/ADRD. MA plans have unique features which 
may impact the type of beneficiaries who enroll and disenroll from plans and provider 
documentation of AD/ADRD. Compared to traditional Medicare, MA plans are paid on a risk-
adjusted capitated basis (Centers for Medicare and Medicaid Service's Hierarchical Condition 
Category (CMS-HCC) risk adjustment model), which incentivizes plans to minimize unnecessary 
utilization by providing care management or other innovative services or care options. Using data 
from three large MA insurers,13 we evaluated the diagnosed prevalence of AD/ADRD in 2014 (ICD-9-
CM era) and 2016 (ICD-10-CM era).  
 
Study Data and Methods 
We calculated the annual prevalence of AD/ADRD diagnoses in 2014 (ICD-9-CM) and 2016 
(ICD-10-CM) in three health insurance MA plan providers (Data Partners) that participate in the NIH 
Health Care Systems Research Collaboratory Distributed Research Network (DRN). These Data 
Partners comprise approximately 30% of the MA market. The Data Partners transform their MA 
enrollment and claims to the DRN Common Data Model, which includes demographic information 
(age and sex), dates of coverage, type of coverage (medical, pharmacy), diagnosis codes, and 
procedure codes. 
 We identified all beneficiaries enrolled in an MA plan in 2014 and 2016 who were ≥65 years 
of age and continuously enrolled in plans with medical and drug coverage for at least 183 days, 
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individuals with AD/ADRD using ICD-9 (2014) and ICD-10 (2016) diagnosis codes included in the 
Medicare Chronic Conditions Warehouse algorithms for AD/ADRD (eTable 1).14 The first date of an 
AD/ADRD diagnosis code in any care setting defined cohort entry and served as the index date.   
For beneficiaries with AD/ADRD diagnoses, we determined age and sex on index date of 
cohort entry. To assess comorbidity, we used a window of 183 days before and up to 183 days after 
cohort entry. We calculated the combined comorbidity score as described by Gagne.15 We 
determined cumulative all-cause disenrollment from the enrolled MA plan up to 364 days from the 
index date. Reasons for disenrollment are unknown in DRN data and may include death, enrollment 
in a different MA plan, enrollment in Medicare fee-for-service or discontinuation of a plan. Finally, 
we calculated rates of having a prevalent AD/ADRD diagnosis in 2014 and 2016 overall and stratified 
by age and sex. We calculated prevalence rates by determining the number of beneficiaries with an 
AD/ADRD diagnosis divided by the total number of MA beneficiaries enrolled in the plans without an 
AD/ADRD diagnosis.  
 
Results  
 In 2016, among 3,115,590 total eligible members, 203,695 (6.5%) beneficiaries had an 
AD/ADRD diagnosis. On average, AD/ADRD beneficiaries were 82.4 (SD=7.3) years of age, 61.8% 
female, and had a mean combined comorbidity score of 5.8 (SD=3.4) (Table 1). Overall, 11.4% of 
beneficiaries with prevalent AD/ADRD disenrolled from their plan within 90 days of their index date. 
By 364 days post-index date, 32% of beneficiaries with prevalent AD/ADRD had disenrolled from 
their plan. In 2014, among 2,862,673 total eligible members, 163,499 (5.7%) beneficiaries had an 
AD/ADRD diagnosis code.  The demographic characteristics of 2014 beneficiaries with AD/ADRD 
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 As expected, the prevalence of AD/ADRD diagnoses increased with age and was generally 
greater for females compare to males (Table 2). For example, in 2016 for both 65-69 year old 
females and males the prevalence of AD/ADRD was ~1.4%. However, among those 85+ the 
prevalence of AD/ADRD for females and males was 23.6% and 18.8%, respectively. The 2014 overall 
and age- and sex- stratified diagnosed prevalence rates of AD/ADRD were similar to 2016.  
   
Discussion  
 Our study is the first to report the prevalence of having an AD/ADRD diagnosis among MA 
beneficiaries immediately prior to and following the transition from ICD-9 (2014) to ICD-10 (2016). 
Congruent with studies using Medicare fee-for-service data and nationally representative surveys, 
the prevalence of diagnosed AD/ADRD increased with age and those with AD/ADRD were more likely 
to be female, and had high rates of congestive heart failure and multimorbidity. 7,16 However, age 
and sex stratified prevalence of AD/ADRD among MA beneficiaries were lower than rates reported in 
Medicare fee-for-service data and nationally representative surveys.7,8,11 For example, in 2016 the 
Medicare CMS Chronic Condition Data Warehouse, which uses a 3-year look over period, reported 
the overall diagnosed prevalence of AD/ADRD in Medicare fee-for-service was 9.9% for males and 
13.6% for females.11 In contrast, in our study, which uses a 1-year look over period, the prevalence 
of diagnosed AD/ADRD in MA among males and females was 5.5% and 7.3%, respectively. We used a 
1-year look over period which may be more useful/pragmatic for identifying people living with 
AD/ADRD in health care systems due to the high mortality rate of the disease.  
We observed a modest increase in the prevalence of AD/ADRD diagnoses in 2016 compared 
to 2014. However, comparisons across years should be made with caution. First, differences in rates 
may be due to differences in ICD-9 (2014) and ICD-10 (2016). Second, from 2014 to 2016 providers 
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diagnoses. Third, from year to year health insurance companies offer different benefits (e.g. free 
gym membership) in their MA plans, or change their marketing, so the markets they operate in may 
have a different prevalence of AD/ADRD and the characteristics (e.g., level of impairment) of 
dementia patients they enroll may not be comparable.  
The all-cause disenrollment rates observed in our study are higher than ~17% disenrollment 
rates (excluding mortality) observed in studies of other high-need, high-cost MA beneficiaries.17,18 
This is an important methodologic consideration for AD/ADRD research among MA beneficiaries. 
Multiple factors may contribute to disenrollment and we cannot disentangle those who died.  
Previous research suggests that aspects of MA plan’s feature may be particularly challenging for 
beneficiaries with AD/ADRD and their caregivers (e.g., need for prior authorizations or narrow 
provider networks).19 Providers may also end their contracts with MA plans resulting in higher 
patient costs or requiring patients to find a different provider or a plan that includes the patient’s 
preferred provider.  
There have been several important policy changes in MA which may impact AD/ADRD 
diagnostic rates in the coming years. Starting in 2019, MA plans were permitted to offer long-term 
care services and supports. This may positively impact MA beneficiaries with cognitive impairment, 
increase MA plan retention, and subsequently increase the prevalence of AD/ADRD diagnoses in MA.  
Prior to 2020, the CMS-HCC risk adjustment model, an algorithm which is used to determine 
payments to MA, did not include AD/ADRD. With the inclusion of AD/ADRD in the CMS-HCC risk 
adjustment model it will be important to evaluate trends in the use of AD/ADRD diagnostic codes 
among MA providers.   
Our study has important limitations. First, we measure only AD/ADRD that has been 
submitted on a medical claim by a clinician, not true disease prevalence. Second, we obtained data 
from three MA plans and these plans may not be representative of the broader MA market. Third, 
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death, enrollment in a different MA plan, or enrollment in Medicare fee-for-service. We also do not 
know whether these disenrollment rates are comparable to the general population of MA 
beneficiaries enrolled in these plans. 
 In conclusion, the overall (5.7% in 2014 and 6.5% in 2016) and age and sex stratified 
prevalence of AD/ADRD diagnosis are lower than prevalence rates reported in Medicare fee-for-
service and nationally representative surveys. MA beneficiaries with AD/ADRD are predominately 
female, have multimorbidity, and at one year 30% are no longer enrolled in their MA plan.  
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Table 1. Characteristics of Medicare Advantage Beneficiaries with Alzheimer’s disease and Related 
Dementias in 2014 and 2016.a 
 2014 2016 
Eligible MA population 2,862,673b 3,115,590c 
 2014 (ICD-9-CM) 2016 (ICD-10-CM) 
 Alzheimer’s Disease and 
Related Dementias 
Alzheimer’s Disease and 
Related Dementias 
 n=163,449 n=203,695 
   
Diagnosed Prevalence, (Raw) 5.7% 6.5% 
Mean Age, (SD)  82.6 (7.2) 82.4 (7.3) 
Female Sex, n (%) 102,295 (62.6) 125,787 (61.8) 
Mean Gagne Comorbidity Score, (SD) 4.4 (3.3) 5.8 (3.4) 
Congestive Heart Failure, n (%) 21,607 (13.2) 70,111 (34.4) 
Depression, n (%) 48,254 (29.5) 71,750 (35.2) 
Diabetes, n (%) 58,914 (36.0) 76,329 (37.5) 
Hypertension, n (%) 138,136 (84.5) 177,406 (87.1) 
Renal Failure, n (%) 9,262 (5.7) 66,311 (32.6) 
Cumulative all-cause disenrollmentd, n (%)   
90 days 18,739 (11.5) 23,279 (11.4) 
180 days 33,679 (20.6) 38,504 (18.9) 
270 days 43,977 (26.9) 51,216 (25.1) 
364 days 56,452 (34.5) 65,448 (32.1) 
aComorbidity history was assessed in the 183 days before through 183 days after the index 
code/cohort entry date; one diagnosis code of interest was required to be counted as having the 
comorbidity. 
b 7 eligible beneficiaries without ADRD were excluded due to missing sex data. 
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dIncludes disenrollment due to death, enrollment in a new MA plan, enrollment in Medicare fee-for-
service, or discontinuation of a plan. 
 
 
Table 2. Prevalence of Alzheimer’s Disease and Related Dementias in Medicare Advantage in 2014 
and 2016. 




Number and Prevalence (%) 
of Members with 





Number and Prevalence (%) 
of Members with 
Alzheimer’s Disease and 
Related Dementias 
 2014 a 
Overall 1,586,616 102,295 (6.4) 1,276,057 61,154 (4.8) 
65-69 
years 364,082 3,723 (1.0) 309,089 2,938 (1.0) 
70-74 
years 454,081 11,688 (2.6) 391,654 9,275 (2.4) 
75-79 
years 334,217 18,708 (5.6) 280,596 13,481 (4.8) 
80-84 
years 232,044 24,720 (10.7) 175,505 15,466 (8.8) 
85+ 
years 202,192 43,456 (21.5) 119,213 19,994 (16.8) 
 2016b 
Overall 1,711,702 125,787 (7.3) 1,403,888 77,908 (5.5) 
65-69 
years 382,997 5,448 (1.4) 334,495 4,367 (1.3) 
70-74 
years 477,020 14,562 (3.1) 416,124 11,538 (2.8) 
75-79 
years 379,430 23,671 (6.2) 322,636 17,411 (5.4) 
80-84 
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years 
85+ 
years 221,728 52,294 (23.6) 135,496 25,454 (18.8) 
a 7 eligible beneficiaries without ADRD were excluded due to missing sex data. 
b 6 eligible beneficiaries without ADRD were excluded due to missing sex data. 
 
 
 
